Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
92 participants
INTERVENTIONAL
2017-05-01
2018-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Periodontal Health and Quality of Life in Psoriasis Patients
NCT07154420
Pathogenesis of Periodontal Disease in Individuals With Psoriasis
NCT07158125
Impact of Non-surgical Periodontal Therapy in the Management of Plaque Psoriasis.
NCT05311501
Salivary Proteome in Response to Non-surgical Periodontal Treatment
NCT05952895
Effects Of Different Periodontal Treatments On Quality Of Life In Patients With Periodontitis
NCT06539364
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test Group
Psoriatic measurements and saliva samples were taken from periodontal disease patients before treatment and after 8 weeks.
Intervention: Non-surgical periodontal treatment was performed and the Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken.
Psoriatic measurements
Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
Non-surgical periodontal treatment
Non-surgical periodontal treatment was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
saliva samples
Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
Control Group
Psoriatic measurements and saliva samples were taken from periodontal disease patients at the baseline and after 8 weeks without the periodontal treatment.
Intervention: Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken.
Psoriatic measurements
Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
saliva samples
Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Psoriatic measurements
Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
Non-surgical periodontal treatment
Non-surgical periodontal treatment was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
saliva samples
Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* the presence of Stage I or Stage II Periodontitis,
* the presence of diagnosed psoriasis.
Exclusion Criteria
* patients who received periodontal treatment prior to 6 months,
* women who were breastfeeding or pregnant,
* patients using medicines such as antibiotics, anti-inflammatory drugs, immune-suppressants.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ozge Gokturk
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ozge Gokturk
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Atiye Ogrum
Role: PRINCIPAL_INVESTIGATOR
Gaziosmanpasa Universty
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gaziosmanpasa University
Tokat Province, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17-KAEK-44
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.